FLT3 and acute myeloid leukemia: Lastly, the type II inhibitor quizartinib—an oral, highly potent, and selective next-generation FLT3 inhibitor [56, 82, 83]—has been evaluated in QuANTUM-R, a global, randomized, open-label, phase 3 study (NCT02039726) examining the effect of quizartinib monotherapy vs. salvage chemotherapy (randomized 2:1) on OS in 367 patients with FLT3-ITD-mutated AML who are refractory to or have relapsed after first-line therapy.